Nasimul Hoda

List of Publications by Year
in descending order

28 papers	1,107 citations	516710 16 h-index	501196 28 g-index
29 all docs	29 docs citations	29 times ranked	1766 citing authors

#	Article	IF	Citations
1	Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics. RSC Medicinal Chemistry, 2022, 13, 258-279.	3.9	15
2	Quinoline carboxamide core moiety-based compounds inhibit P. falciparumfalcipain-2: Design, synthesis and antimalarial efficacy studies. Bioorganic Chemistry, 2021, 108, 104514.	4.1	14
3	An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins. European Journal of Medicinal Chemistry, 2021, 210, 112955.	5.5	15
4	Unravelling the potency of triazole analogues for inhibiting Î±-synuclein fibrillogenesis andin vitrodisaggregation. Organic and Biomolecular Chemistry, 2021, 19, 1589-1603.	2.8	5
5	Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimerâ€™s action: Design, synthesis, crystal structure and in-vitro biological evaluation. European Journal of Medicinal Chemistry, 2021, 215, 113224.	5.5	37
6	Novel triazole-sulfonamide bearing pyrimidine moieties with carbonic anhydrase inhibitory action: Design, synthesis, computational and enzyme inhibition studies. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128249.	2.2	20
7	Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimerâ€™s disease. Bioorganic Chemistry, 2021, 116, 105354.	4.1	13
8	A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimerâ€™s disease agents: A review. European Journal of Medicinal Chemistry, 2020, 206, 112787.	5.5	123
9	Diphenyl triazine hybrids inhibit Î±-synuclein fibrillogenesis: Design, synthesis and inÂvitro efficacy studies. European Journal of Medicinal Chemistry, 2020, 207, 112705.	5.5	9
10	Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting Î±-synuclein in transgenic C. elegans model of Synucleinopathy. Bioorganic and Medicinal Chemistry, 2020, 28, 115640.	3.0	6
11	Naphthalene-triazolopyrimidine hybrid compounds as potential multifunctional anti-Alzheimerâ€™s agents. Bioorganic and Medicinal Chemistry, 2019, 27, 3156-3166.	3.0	16
12	A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 175, 2-19.	5.5	53
13	Pyrimidineâ€Triazolopyrimidine and Pyrimidineâ€Pyridine Hybrids as Potential Acetylcholinesterase Inhibitors for Alzheimer's Disease. ChemistrySelect, 2018, 3, 736-747.	1.5	24
14	New amyloid beta-disaggregating agents: synthesis, pharmacological evaluation, crystal structure and molecular docking of N-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl)amines. MedChemComm, 2018, 9, 1891-1904.	3.4	10
15	Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules. Current Topics in Medicinal Chemistry, 2018, 17, 3370-3389.	2.1	31
16	Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents. European Journal of Medicinal Chemistry, 2017, 136, 36-51.	5.5	55
17	Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study. Journal of Molecular Modeling, 2017, 23, 7.	1.8	9
18	Design, synthesis, and biological evaluation of pyrimidine derivatives as potential inhibitors of human calcium/calmodulinâ€dependent protein kinase <scp>IV</scp>. Chemical Biology and Drug Design, 2017, 89, 741-754.	3.2	28

#	Article	IF	Citations
19	Dihydroorotate dehydrogenase: A drug target for the development of antimalarials. European Journal of Medicinal Chemistry, 2017, 125, 640-651.	5.5	52
20	De novo lead optimization of triazine derivatives identifies potent antimalarials. Journal of Molecular Graphics and Modelling, 2017, 71, 96-103.	2.4	8
21	GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future. Current Pharmaceutical Design, 2017, 23, 4332-4350.	1.9	54
22	Development of cyanopyridineâ€“triazine hybrids as lead multitarget anti-Alzheimer agents. Bioorganic and Medicinal Chemistry, 2016, 24, 2777-2788.	3.0	48
23	Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies. European Journal of Medicinal Chemistry, 2016, 119, 260-277.	5.5	55
24	Coumarin: A Privileged Scaffold for the Design and Development of Antineurodegenerative Agents. Chemical Biology and Drug Design, 2016, 87, 21-38.	3.2	100
25	Structure guided design of potential inhibitors of human calciumâ€“calmodulin dependent protein kinase IV containing pyrimidine scaffold. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 782-788.	2.2	34
26	Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. European Journal of Medicinal Chemistry, 2016, 107, 63-81.	5.5	191
27	Curcumin specifically binds to the human calciumâ€“calmodulin-dependent protein kinase IV: fluorescence and molecular dynamics simulation studies. Journal of Biomolecular Structure and Dynamics, 2016, 34, 572-584.	3.5	68
28	Selective inhibitors of phosphodiesterases: therapeutic promise for neurodegenerative disorders. MedChemComm, 2015, 6, 2063-2080.	3.4	14